专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007020286A3 METHOD OF USING POTASSIUM CHANNEL INHIBITING COMPOUNDS 审中-公开
标题翻译：使用钾通道抑制化合物的方法
公开(公告)号：WO2007020286A3
公开(公告)日：2007-05-10
申请号：PCT/EP2006065418
申请日：2006-08-17
申请人： SOLVAY PHARM GMBH , ANTEL JOCHEN , GREGORY PETER-COLIN , FIRNGES MICHAEL , REICHE DANIA
发明人： ANTEL JOCHEN , GREGORY PETER-COLIN , FIRNGES MICHAEL , REICHE DANIA
IPC分类号： A61K31/549 , A61K31/085 , A61K31/415 , A61K31/4155 , A61K31/4439 , A61K31/5383 , A61P3/00 , A61P3/04 , A61P3/10 , A61P9/00 , A61P11/06 , A61P13/10 , A61P17/14 , A61P25/00 , A61P25/08
CPC分类号： A61K31/425 , A61K31/085 , A61K31/415 , A61K31/4155 , A61K31/4439 , A61K31/5383 , A61K31/549 , A61K45/06 , A61K2300/00
摘要： The present invention relates to the use of an effective amount of at least one potassium KvI.3 channel inhibitor or of an effective amount of at least one compound having in addition to its potassium KvI.3 channel inhibiting properties also CBx modulating properties and/or potassium K(atp) channel opening properties for the manufacture of a medicament for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of various medical conditions in subjects in need thereof . The diseases are obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, glucose metabolism - in particular, insulin resistance, hyperglycaemea and/or glucose intolerance - neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence. The compounds are a.o. 4, 5-dihydropyrazole derivatives, imidazole derivatives, diazoxide, NN414, R(+) -WIN55212-2, HU-308, Rimonaband, SR-147778.
摘要翻译：本发明涉及使用有效量的至少一种KvI.3通道抑制剂或有效量的至少一种化合物，除了其KvI.3通道抑制性质之外，还具有CBx调节性质和/或钾（atp）通道开放性质，用于制备用于在有需要的受试者中预防，治疗，延迟进展，延迟发作和/或抑制各种医学病症的药物。疾病是肥胖症，糖尿病，代谢综合征，综合征X，胰岛素瘤，家族性高胰岛素血症，男性型秃发，逼尿肌反应性过高，哮喘，葡萄糖代谢 - 特别是胰岛素抵抗，高血糖和/或葡萄糖不耐受 - 神经保护，癫痫，止痛心脏保护，心绞痛，心脏停搏，心律失常，冠状动脉痉挛，外周血管疾病，脑血管痉挛，食欲调节，神经变性，疼痛 - 包括神经性疼痛和慢性疼痛 - 阳。。化合物是a.o. 4,5-二氢吡唑衍生物，咪唑衍生物，二氮嗪，NN414，R（+）-WIN55212-2，HU-308，Rimonaband，SR-147778。

2. 发明申请

WO2005110413A2 MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS 审中-公开
标题翻译：含有丙型肝炎病毒的药物，用于预防或治疗肥胖症及相关病症
公开(公告)号：WO2005110413A2
公开(公告)日：2005-11-24
申请号：PCT/EP2005/052281
申请日：2005-05-18
申请人： SOLVAY PHARMACEUTICALS GMBH , ANTEL, Jochen , GREGORY, Peter-Colin , REINECKER, Uwe , WURL, Michael , SCHOEN, Uwe , WALDECK, Harald , FIRNGES, Michael , REICHE, Dania
发明人： ANTEL, Jochen , GREGORY, Peter-Colin , REINECKER, Uwe , WURL, Michael , SCHOEN, Uwe , WALDECK, Harald , FIRNGES, Michael , REICHE, Dania
IPC分类号： A61K31/495
CPC分类号： A61K31/495 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/53 , C07D213/74 , C07D295/26
摘要： The present invention relates to the use of known and novel N-sulfamoyl-N'arylpiperazines and their physiologically compatible acid addition salts for the prophylaxis or treatment of obesity and related conditions.
摘要翻译：本发明涉及已知和新型N-氨磺酰-N-芳基哌嗪及其生理上相容的酸加成盐在预防或治疗肥胖症及相关病症中的用途。

3. 发明申请

WO2007125049A1 USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS 审中-公开
标题翻译： CBX CANNABINOID受体调节剂作为钾通道调节剂的使用
公开(公告)号：WO2007125049A1
公开(公告)日：2007-11-08
申请号：PCT/EP2007/053915
申请日：2007-04-20
申请人： SOLVAY PHARMACEUTICALS GMBH , ANTEL, Jochen , GREGORY, Peter-Colin , LANGE, Josephus Hubertus Maria , FIRNGES, Michael , REICHE, Dania
发明人： ANTEL, Jochen , GREGORY, Peter-Colin , LANGE, Josephus Hubertus Maria , FIRNGES, Michael , REICHE, Dania
IPC分类号： A61K31/353 , A61K31/425 , A61K31/415 , A61K31/454 , A61K31/09 , A61K31/542 , A61K31/5415 , A61P3/04 , A61P3/10 , A61P9/06 , A61P9/10 , A61P13/10 , A61P15/10 , A61P17/14 , A61P25/28
CPC分类号： A61K31/09 , A61K31/353 , A61K31/415 , A61K31/425 , A61K31/454 , A61K31/5415 , A61K31/542
摘要： The invention is directed to the use of at least one CB x modulator wherein the CB x modulator is selected from the group consisting of CB 1 agonists; CB 2 agonists; CB 2 partial agonists; CB 2 antagonists; CB 2 inverse agonists; and dually acting compounds which are both a CB 1 agonist and a CB 2 agonist; and mixtures thereof, as K ATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CB x modulator having K ATP channel modulating properties.
摘要翻译：本发明涉及使用至少一种CB-X调节剂，其中CB调节剂选自CB 1激动剂 ; CB 2激动剂; CB 2/2部分激动剂; CB 2拮抗剂; CB 2反向激动剂; 和作为CB 1激动剂和CB 2 N 2激动剂的双作用化合物; 和其混合物，作为用于预防，治疗，延迟进展，延迟发作和/或抑制多种疾病状况（包括肥胖症，糖尿病，代谢综合征，综合征X，胰岛素瘤）的K ATP通道调节剂，家族性高胰岛素低血糖，男性型秃发，逼尿肌反应性过高，哮喘，神经保护，癫痫，镇痛，心脏保护，心绞痛，心跳停搏，心律失常，冠状动脉痉挛，外周血管疾病，脑血管痉挛，食欲调节，神经变性，疼痛 - 包括神经性疼痛和慢性疼痛和哺乳动物和人类的阳。。本发明还涉及治疗，预防，延缓发病和/或抑制各种疾病状况（包括肥胖症，糖尿病，代谢综合征，综合征X，胰岛素瘤，家族性高胰岛素低血糖，男性型秃发，逼尿肌）的进展，高反应性，哮喘，神经保护，癫痫，止痛，心脏保护，心绞痛，心脏停跳，心律失常，冠状动脉痉挛，外周血管疾病，脑血管痉挛，食欲调节，神经变性，疼痛 - 包括神经性疼痛和慢性疼痛 - 以及哺乳动物和人的阳humans 涉及有需要的受试者有效量的至少一种具有K ATP通道调节特性的CB调节剂。

4. 发明申请

WO2007065948A1 NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS 审中-公开
标题翻译：用于预防或治疗肥胖及相关情况的新型N-磺酰胺哌啶胺
公开(公告)号：WO2007065948A1
公开(公告)日：2007-06-14
申请号：PCT/EP2006/069482
申请日：2006-12-08
申请人： SOLVAY PHARMACEUTICALS GMBH , ANTEL, Jochen , SCHOEN, Uwe , WALDECK, Harald , WURL, Michael , FIRNGES, Michael , REICHE, Dania , GREGORY, Peter-Colin
发明人： ANTEL, Jochen , SCHOEN, Uwe , WALDECK, Harald , WURL, Michael , FIRNGES, Michael , REICHE, Dania , GREGORY, Peter-Colin
IPC分类号： C07D211/58 , C07D401/04 , C07D409/12 , C07D401/12 , A61K31/4545 , A61P3/04
CPC分类号： C07D409/12 , C07D211/58 , C07D401/04 , C07D401/12
摘要： The present invention relates to novel N-sulfamoyl-piperidineamides of general formula (I) and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and/or related conditions.
摘要翻译：本发明涉及通式（I）的新型N-氨磺酰 - 哌啶酰胺及其生理上可接受的酸加成盐，涉及包含它们的药物组合物，其制备方法及其用于治疗肥胖及其伴随和/或继发性疾病和/或相关病症。

5. 发明申请

WO2006045799A3 PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS 审中-公开
公开(公告)号：WO2006045799A3
公开(公告)日：2006-05-04
申请号：PCT/EP2005/055534
申请日：2005-10-25
申请人： SOLVAY PHARMACEUTICALS GMBH , FIRNGES, Michael , GREGORY, Peter-Colin , ANTEL, Jochen , LANGE, Josephus Hubertus Maria , WALDECK, Harald
发明人： FIRNGES, Michael , GREGORY, Peter-Colin , ANTEL, Jochen , LANGE, Josephus Hubertus Maria , WALDECK, Harald
IPC分类号： A61K31/00 , A61K31/54 , A61K31/40 , A61K31/44 , A61K31/415 , A61K31/427 , C12Q1/68 , A61P3/04 , G01N33/00
摘要： Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one K ATP channel opener as a first active agent and at least one CB1 cannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined KATP channel opening and CB 1 antagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising K ATP channel openers and CB1 antagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type I, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhibition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined K ATP channel opening and CB 1 antagonistic properties.

6. 发明申请

WO2007125048A1 PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS 审中-公开
标题翻译：包含CBX CANNABINOID受体调节剂和钾通道调节剂的药物组合物
公开(公告)号：WO2007125048A1
公开(公告)日：2007-11-08
申请号：PCT/EP2007/053914
申请日：2007-04-20
申请人： SOLVAY PHARMACEUTICALS GMBH , ANTEL, Jochen , GREGORY, Peter-Colin , LANGE, Josephus Hubertus Maria , FIRNGES, Michael , REICHE, Dania
发明人： ANTEL, Jochen , GREGORY, Peter-Colin , LANGE, Josephus Hubertus Maria , FIRNGES, Michael , REICHE, Dania
IPC分类号： A61K31/415 , A61K31/426 , A61K31/045 , A61P9/00 , A61P3/00
CPC分类号： A61K31/045 , A61K31/415 , A61K31/426 , A61K2300/00
摘要： The invention is directed to pharmaceutical compositions comprising pharmacologically effective quantities of each of a) at least one K ATP channel modulator as a first active agent and b) at least one CB x modulator as a second active agent. The invention further relates to the use of such compositions and to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans by administering such compositions to subjects in need thereof. The invention also is directed to processes of manufacturing such compositions.
摘要翻译：本发明涉及药物组合物，其包含药理学有效量的a）至少一种作为第一活性剂的至少一种ATP通道调节剂，和b）至少一种CB 调节剂作为第二活性剂。本发明还涉及这样的组合物的用途，以及治疗，预防，延缓发病和/或抑制多种疾病状况（包括肥胖症，糖尿病，代谢综合征，综合征X，胰岛素瘤，家族性高胰岛素）的方法低血糖，男性型秃发，逼尿肌反应过度，哮喘，神经保护，癫痫，止痛，心脏保护，心绞痛，心脏停跳，心律失常，冠状动脉痉挛，外周血管疾病，脑血管痉挛，食欲调节，神经变性，疼痛 - 包括神经性疼痛和慢性疼痛通过将这些组合物给予有需要的受试者，在哺乳动物和人类中发挥阳。。本发明还涉及制造这种组合物的方法。

7. 发明申请

WO2007063086A1 NOVEL NK1 AND NK2 ANTAGONISTS 审中-公开
标题翻译：新的NK1和NK2拮抗剂
公开(公告)号：WO2007063086A1
公开(公告)日：2007-06-07
申请号：PCT/EP2006/069087
申请日：2006-11-30
申请人： SOLVAY PHARMACEUTICALS GMBH , JASSERAND, Daniel , SCHOEN, Uwe , ANTEL, Jochen , FIRNGES, Michael , REICHE, Dania , SANN, Holger , BRÜCKNER, Reinhard
发明人： JASSERAND, Daniel , SCHOEN, Uwe , ANTEL, Jochen , FIRNGES, Michael , REICHE, Dania , SANN, Holger , BRÜCKNER, Reinhard
IPC分类号： C07D213/38 , C07D295/12 , C07D307/52 , C07D307/81 , C07D317/58 , C07D333/20 , C07D333/28 , C07D333/58 , C07D407/06 , C07D409/06 , A61K31/4965 , A61K31/497 , A61P1/00
CPC分类号： C07D295/13 , C07D213/38 , C07D295/125 , C07D307/52 , C07D307/81 , C07D317/58 , C07D333/20 , C07D333/28 , C07D333/58 , C07D407/06 , C07D409/06
摘要： The present invention relates to novel 3-cyano-naphthalene-1-carboxylic acid perhydroxyalkylmethyl-piperazine compounds of formula I which are antagonistic to tachykinin receptors. The present invention is further directed to pharmaceutical compositions comprising such compounds, to processes for the preparation of such compounds and to intermediate products of these processes.
摘要翻译：本发明涉及对速激肽受体有拮抗作用的式I的新型3-氰基 - 萘-1-羧酸全羟基烷基甲基 - 哌嗪化合物。本发明还涉及包含这些化合物的药物组合物，用于制备这些化合物的方法和这些方法的中间产物。

8. 发明申请

WO2006045799A2 PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS 审中-公开
标题翻译：包含CB1大麻素受体拮抗剂和钾通道开放剂的药物组合物用于治疗I型糖尿病，肥胖症和相关病症
公开(公告)号：WO2006045799A2
公开(公告)日：2006-05-04
申请号：PCT/EP2005055534
申请日：2005-10-25
申请人： SOLVAY PHARM GMBH , FIRNGES MICHAEL , GREGORY PETER-COLIN , ANTEL JOCHEN , LANGE JOSEPHUS HUBERTUS MARIA , WALDECK HARALD
发明人： FIRNGES MICHAEL , GREGORY PETER-COLIN , ANTEL JOCHEN , LANGE JOSEPHUS HUBERTUS MARIA , WALDECK HARALD
IPC分类号： A61K31/00 , A61K31/40 , A61K31/415 , A61K31/427 , A61K31/44 , A61K31/54 , A61P3/04 , C12Q1/68 , G01N33/00
CPC分类号： A61K31/00 , A61K31/40 , A61K31/415 , A61K31/4152 , A61K31/427 , A61K31/44 , A61K31/4439 , A61K31/454 , A61K31/5377 , A61K31/54 , A61K31/655 , A61K45/06 , G01N33/6872 , G01N33/948 , G01N2500/00 , G01N2800/042 , G01N2800/044 , A61K2300/00
摘要： Described is a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at least one K ATP channel opener as a first active agent and at least one CB1 cannabinoid receptor antagonist as a second active agent. The invention is further directed to such novel combination therapy wherein a dually acting compound with combined KATP channel opening and CB 1 antagonistic properties is used. The invention also relates to novel pharmaceutical compositions comprising K ATP channel openers and CB1 antagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset of and/or inhibition of diabetes mellitus type I, and the prophylaxis and treatment, of obesity as well as the prophylaxis, treatment, delayed onset and/or inhibition of its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, in mammals and humans. The invention is further directed to such novel pharmaceutical compositions comprising a dually acting compound with combined K ATP channel opening and CB 1 antagonistic properties.
摘要翻译：描述了用于I型糖尿病和/或肥胖症及其伴随和/或继发性疾病或病症，特别是代谢综合征和/或X综合征和/或II型糖尿病的新型组合疗法，其通过施用组合疗法作为第一活性剂的至少一种K ATP通道开放剂和作为第二活性剂的至少一种CB 1大麻素受体拮抗剂。本发明还涉及这种新的组合疗法，其中使用具有组合KATP通道开放和CB1 /拮抗性质的双重作用化合物。本发明还涉及包含ATP通道开放剂和CB1拮抗剂的新型药物组合物，以及所述药物组合物在治疗，延缓进展，延迟发作和/或抑制I型糖尿病中的用途，以及肥胖的预防和治疗以及其伴随和/或继发疾病或病症，特别是代谢综合征和/或X综合征和/或糖尿病类型的预防，治疗，延迟发作和/或抑制 II，哺乳动物和人类。本发明进一步涉及这种新颖的药物组合物，其包含具有组合K _{ATP通道开放和CB1 /拮抗性质的双重作用化合物。}

9. 发明申请

WO2007088181A1 NOVEL DUAL NK2/NK3-ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PROCESSES FOR THEIR PREPARATIONS 审中-公开
标题翻译：新型二NK2 / NK3拮抗剂，包含它们的药物组合物及其制备方法
公开(公告)号：WO2007088181A1
公开(公告)日：2007-08-09
申请号：PCT/EP2007/050964
申请日：2007-02-01
申请人： SOLVAY PHARMACEUTICALS GMBH , JASSERAND, Daniel , MENTZEL, Matthias , JAUNZEMS, Janis , BENSON, Werner , PREUSCHOFF, Ulf , FIRNGES, Michael , SANN, Holger , BRÜCKNER, Reinhard , ADOLFS, Martinus , ATTALI, Amos
发明人： JASSERAND, Daniel , MENTZEL, Matthias , JAUNZEMS, Janis , BENSON, Werner , PREUSCHOFF, Ulf , FIRNGES, Michael , SANN, Holger , BRÜCKNER, Reinhard , ADOLFS, Martinus , ATTALI, Amos
IPC分类号： C07D211/66 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D401/04 , C07D211/62 , C07D295/14 , C07D211/58 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/445
CPC分类号： C07D211/66 , C07D211/58 , C07D211/62 , C07D295/155 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要： The present invention relates to novel dual NK2/NK3-antagonists of formula (I) wherein the meaning of X and R1 to R5 is defined in the claims and in the description and also to pharmaceutical compositions comprising these compounds. Furthermore, the invention relates to processes for the preparation of the novel dual NK2/NK3-antagonists and to their uses.
摘要翻译：本发明涉及式（I）的新型双NK2 / NK3拮抗剂，其中X和R 1至R 5的含义在权利要求书和说明书中以及包含这些化合物的药物组合物中定义。此外，本发明涉及制备新的双NK2 / NK3拮抗剂及其用途的方法。

10. 发明申请

WO2007054580A1 N-SULFAMOYL-N’-BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES 审中-公开
标题翻译：作为碳氢化合物的抑制剂的N-磺酰基-N-苯并吡喃酮
公开(公告)号：WO2007054580A1
公开(公告)日：2007-05-18
申请号：PCT/EP2006/068416
申请日：2006-11-14
申请人： SOLVAY PHARMACEUTICALS GMBH , ANTEL, Jochen , WALDECK, Harald , SCHOEN, Uwe , GREGORY, Peter-Colin , WURL, Michael , FIRNGES, Michael , REICHE, Dania , REINECKER, Uwe
发明人： ANTEL, Jochen , WALDECK, Harald , SCHOEN, Uwe , GREGORY, Peter-Colin , WURL, Michael , FIRNGES, Michael , REICHE, Dania , REINECKER, Uwe
IPC分类号： C07D491/10 , C07D491/20 , A61K31/438 , A61P27/06 , A61P25/00 , A61P3/00 , A61P35/00
CPC分类号： C07D491/10
摘要： The present invention relates to novel N-sulfamoyl-N'-benzopyranpiperidines of general formula (I) and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the prophylaxis and/or treatment and/or prevention and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and its concomitant and/or secondary diseases or conditions.
摘要翻译：本发明涉及通式（I）的新型N-氨磺酰基-N'-苯并吡喃哌啶及其生理上可接受的酸加成盐，包括它们的药物组合物，其制备方法及其用于预防和/或治疗和 /或预防和/或抑制青光眼，癫痫，双相性精神障碍，偏头痛，神经性疼痛，肥胖症，II型糖尿病，代谢综合征，酒精依赖和/或癌症及其并发症和/或继发性疾病或病症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式